Bristol-Myers Squibb (NY, USA) have announced that they will be acquiring Celgene (NJ, USA) this year for a cost of $74 billion.
Richard Hucker (A4P Codescribes key trends, challenges and what the future may hold for bioanalytical outsourcing.
Find out what Marco Michi (Aptuit) has to say about the future of bioanalytical outsourcing, in this expert interview.
Best practices in performing flow cytometry in a regulated environment: feedback from experience within the European Bioanalysis Forum
In this manuscript, the European Bioanalysis Forum presents additional practice guidance on the use of flow cytometry in the support of drug development programs and addresses areas that are not covered in the previous publications.
Find out what Kevin Vernarec (QPS) thinks about how outsourcing might change in the future in this expert interview.
Quantitative biodistribution of biotherapeutics at whole body, organ and cellular levels by autoradiography
Tools for mapping and quantifying monoclonal antibody (mAb) and peptide biotherapeutics distribumtion were evaluated by comparing data from three independent methods conducted at the whole body, organ or tissue, and cellular levels.
This week’s round-up includes the discovery of a novel method for mass spectometry and thermal desorption, as well as an update from Waters Corp (MA, USA) on their aquisition of DESI technology exclusive rights.
Find out more about the co-development agreement between Xbrane and STADA for a ranibizumab biosimilar, and about a novel biomarker test for establishing lung cancer risk in smokers in this week’s bioanalytical news round-up.
Read more about the top stories in new technology developments in this week’s news round-up.
BioAgilytix (NC, USA) have announced their partnership with Sword Bio (IL, USA), to expand their bioanalytical services to include Sword Bio’s detection platform for immunoassays.